Meta Information

ID:estradiol-cypionate

Name:Estradiol Cypionate

Schema Version:1.5

Alternate Names

• Depo-Estradiol

Active Compound

Estradiol

Intervention Type

therapeutic_agent

Delivery

Route:

intramuscular_or_subcutaneous_injection

Scope:

• systemic

Regulatory Status

• us:rx_drug
• eu:rx_drug

Indication

Focus:

disease_treatment

Description:

Treatment of moderate to severe vasomotor symptoms (e.g., hot flashes) and vulvovaginal atrophy associated with menopause.

Typical Protocol

• Typically 1-5 mg injected intramuscularly every 3 to 4 weeks for menopausal symptoms.

Expected Cost Mean

Low Cost:

20

High Cost:

60

Cost Type:

monthly

Description:

Vial and supply costs; often covered by insurance for approved indications.

Summary

Estradiol cypionate is a long-acting, bioidentical form of estrogen used in hormone replacement therapy. It works by replacing the declining levels of estrogen in menopausal women, thereby binding to estrogen receptors throughout the body to alleviate symptoms like hot flashes, night sweats, and vaginal atrophy.

Purpose

Replaces estrogen to treat moderate-to-severe symptoms caused by menopause.

Card Summary

A long-acting injectable estrogen that replaces declining hormone levels to treat menopausal symptoms.

Drug Class

estrogen_receptor_agonists

Drugs In Class

Empty Array

Impact

Score:

8.5

Justification:

Highly effective, first-line therapy for alleviating moderate to severe menopausal vasomotor symptoms.

Evidence

Grade:

A

Score:

9.5

Justification:

Extensive evidence from numerous large-scale RCTs and decades of clinical use.

Safety

Score:

6.5

Justification:

Requires medical supervision due to risks of thrombosis, stroke, and certain cancers.

Flags

• Increased risk of venous thromboembolism (VTE), stroke, and myocardial infarction.
• Unopposed estrogen increases the risk of endometrial hyperplasia and cancer in women with a uterus.
• May increase the risk of breast cancer with long-term use.
• Contraindicated in individuals with a history of certain cancers, VTE, or liver disease.
• Requires co-administration with a progestin for uterine protection in women with a uterus.

Verdict

Highly effective for menopausal symptoms; requires careful medical risk assessment.

Qualifier

route: IM, SQ Injection, scope: systemic, focused on disease treatment

Created

2026-05-08T02:29:14.942341Z

Ai Model

Gemini 2.5 Pro (High)